Extract
Asthma and obesity are prevalent disorders with significant impact on public health. Obesity is a reported risk factor for the development of asthma and is associated with increased exacerbation rates, medication usage and higher symptoms scores in patients with asthma. It should therefore be addressed and treated as an important asthma related co-morbidity [1]. Oral corticosteroids (OCS) are widely prescribed for asthma exacerbations and for chronic management of severe asthma despite well-known adverse side effects, including weight gain. Biologic therapies for severe asthma reduce exacerbation rates and the anti-IL5/5R biologic therapies mepolizumab and benralizumab are effective steroid-sparing agents [2–6]. It remains unknown whether long-term use of these treatments supports weight loss in overweight and obese individuals previously exposed to maintenance or frequent OCS. Eosinophils have been postulated to play a role in metabolic homeostasis and promote energy expenditure [6]. Consequently, one could assume that eosinophil depleting biologics theoretically lead to weight gain after prolonged exposure.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: L. Thomson reports speaker fees and conference trave support from Astra Zeneca.
Conflict of interest: C. Roxas reports speaker fees from AstraZeneca, Chiesi, NAPP and Novartis and conference travel support from AstraZeneca, Chiesi, GlaxoSmithKline, NAPP, Novartis.
Conflict of interest: J. Dhariwal reports congress support from Sanofi.
Conflict of interest: J. E. Kavanagh reports travel support from Teva.
Conflict of interest: A.M. Nanzer reports speaker fees and conference travel support from AstraZeneca, Sanofi, Teva, Chiesi and Napp.
Conflict of interest: G. d'Ancona, reports advisory board, speaker fees and congress travel support from GlaxoSmithKline, AstraZeneca, Chiesi, Napp, and Teva Pharmaceuticals.
Conflict of interest: B. D. Kent reports advisory board fees from AstraZeneca, GlaxoSmithKline and Chiesi, speaker fees from GlaxoSmithKline and AstraZeneca, and travel support to attend ERS meetings from A Menarini.
Conflict of interest: D. J. Jackson reports investigator43 initiated research grants from AstraZeneca, advisory board and speaker fees from AstraZeneca, Sanofi and GlaxoSmithKline.
Conflict of interest: The rest of the authors declare that they have no relevant conflicts of interest.
- Received February 20, 2023.
- Accepted June 25, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org